Galecto, Inc. (GLTO)
| Market Cap | 4.67M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.50M |
| Shares Out | 1.32M |
| EPS (ttm) | -15.20 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,732 |
| Open | 3.410 |
| Previous Close | 3.470 |
| Day's Range | 3.264 - 3.813 |
| 52-Week Range | 2.010 - 16.068 |
| Beta | 1.35 |
| Analysts | Buy |
| Price Target | 10.00 (+182.89%) |
| Earnings Date | Aug 11, 2025 |
About GLTO
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for GLTO stock is "Buy" and the 12-month stock price target is $10.0.
News
Galecto Reports First Quarter 2025 Operating and Financial Results
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced ...
Galecto Reports Full-Year 2024 Financial Results
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced ...
Galecto to Participate in Upcoming Investor Conferences
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, toda...
Galecto Reports Third Quarter 2024 Financial Results
- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of ...
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced t...
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced t...
Galecto Announces Reverse Stock Split
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced t...
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keyt...
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a cli...
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three weeks Partial response seen in three of five pa...
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced ...
Galecto Biotech Collapse: Opportunity For Galectin Therapeutics
Galecto Biotech's stock has plummeted 75% due to increased rates of adverse events in its idiopathic pulmonary fibrosis (IPF) trial. Galecto's synthetic, small molecule approach to galectin-3 inhibiti...
Galecto to Present at Investor Conferences in September
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for f...
Galecto shares drop 65% as biotech halts development of lung-disease treatment
Shares of Galecto Inc. GLTO dropped 65% in premarket trading Tuesday after the biotech company said it would drop an investigational treatment for idiopathic pulmonary fibrosis, a chronic lung disease...
Galecto to discontinue development of lung disease treatment
Drug developer Galecto said on Tuesday it will discontinue development of its lung disease treatment after it failed to meet its primary goal in a mid-stage study.
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Announces next steps for clinical development plan in severe liver diseases Announces next steps for clinical development plan in severe liver diseases
Galecto Reports Second Quarter Operating and Financial Results
BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for f...
Galecto Set to Join Russell Microcap® Index
BOSTON, June 20, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for f...
Galecto to Present at the Upcoming Jefferies Healthcare Conference
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fi...
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fi...
Galecto to Present Poster at Upcoming ATS 2023 International Conference
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fi...
Galecto Reports First Quarter Operating and Financial Results
BOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for ...
Galecto: Promising Pipeline And Excellent Risk-Reward
Galecto: Promising Pipeline And Excellent Risk-Reward
Galecto to Present Two Posters at AACR Annual Meeting 2023
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for ...
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
BOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for ...